Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rapport Therapeutics (RAPP) Operating Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Operating Expenses data on record, last reported at $44.2 million in Q1 2026.

  • On a quarterly basis, Operating Expenses rose 63.11% to $44.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $142.2 million, a 52.8% increase, with the full-year FY2025 number at $125.1 million, up 50.62% from a year prior.
  • Operating Expenses reached $44.2 million in Q1 2026 per RAPP's latest filing, up from $38.5 million in the prior quarter.
  • Over the last five years, Operating Expenses for RAPP hit a ceiling of $44.2 million in Q1 2026 and a floor of $6.6 million in Q2 2023.
  • A 4-year average of $23.6 million and a median of $22.6 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 213.73% in 2024, then surged 38.57% in 2025.
  • Tracing RAPP's Operating Expenses over 4 years: stood at $14.8 million in 2023, then surged by 58.99% to $23.5 million in 2024, then skyrocketed by 63.72% to $38.5 million in 2025, then increased by 14.82% to $44.2 million in 2026.
  • Business Quant data shows Operating Expenses for RAPP at $44.2 million in Q1 2026, $38.5 million in Q4 2025, and $30.0 million in Q3 2025.